Kiroğlu M, Cetik F, Soylu L, Abedi A, Aydoğan B, Akçali C, Kiroğlu F, Ozsahinoğlu C
Department of Otolaryngology, Cukurova University Medical Faculty, Adana, Turkey.
Am J Otolaryngol. 1994 May-Jun;15(3):212-4. doi: 10.1016/0196-0709(94)90007-8.
In this study, we evaluate the effect of acyclovir in the treatment of recurrent respiratory papillomatosis (RRP), in addition to CO2 surgery.
We include 12 patients who had aggressive RRP and required at least three prior endoscopic surgeries in this study. Acyclovir treatment started the day after the surgery. During the planned treatment period of 6 months, patients older than 5 years were asked to take the daily dose of 800 mg, and those younger than 5 years were asked to take 400 mg.
Nine of 12 patients were disease free during the follow-up periods, which ranged from 14 to 25 months with a mean of 18 months. Only 3 patients who used the drug inadequately required reoperation.
Because of the specific viral origin of RRP, we hope that addition of acyclovir to surgery will preclude or at least decrease the number of recurrences in this potentially fatal disease.
在本研究中，我们评估了除二氧化碳手术外，阿昔洛韦在复发性呼吸道乳头状瘤病（RRP）治疗中的效果。
本研究纳入了12例侵袭性RRP患者，这些患者此前至少接受过三次内镜手术。术后次日开始阿昔洛韦治疗。在计划的6个月治疗期内，5岁以上患者每日服用800毫克，5岁以下患者每日服用400毫克。
12例患者中有9例在随访期间无疾病复发，随访期为14至25个月，平均18个月。只有3例未充分使用该药物的患者需要再次手术。
鉴于RRP特定的病毒起源，我们希望手术联合阿昔洛韦能够预防或至少减少这种潜在致命疾病的复发次数。
